Business
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences –
About this update from Cabaletta Bio, Inc.
[{"type":"text","content":"– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 2015 and 2018, leading the worldwide commercialization effort for the CD19-CAR T cell therapy, Yescarta®, and playing a key role in its acquisition by Gilead Sciences, Inc. As part of her appointment to the Board of Directors, Ms. Tomasello will become a member of the Compensation Committee and the newly formed Science & Technology Committee. “Shawn is a recognized biopharmaceutical leader with a proven track record building large-scale commercial organizations to bring transformative therapies to patients in need, including having overseen the global commercial launch of the leading approved CD19-CAR T cell therapy,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. “Shawn’s experience in pre-launch planning, scaling and commercializing a CD19-CAR T therapy globally will provide important additional perspective to our Board of Directors as we continue to expand and advance our CABA-201 development program.” Ms. Tomasello brings over three decades of experience in the life sciences industry and most recently served as the Chief Commercial Officer of Kite Pharma, now part of Gilead Sciences, where she oversaw the global commercialization of Yescarta®, the first approved CAR-T therapy for non-Hodgkin lymphoma. Prior to joining Kite Pharma, she was the Chief Commercial Officer of Pharmacyclics LLC, now part of AbbVie Inc., where she led both commercial and medical affairs. Before that, Ms. Tomasello held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology, where she led the company through five successful product launches encompassing 11 indications and pl...